Annexin Pharmaceuticals AB (publ) announced that the final patient has been treated in the phase II study with ANXV for the eye disease retinal vein occlusion. A total of 15 patients have been treated, and the results so far show a favorable safety profile and promising efficacy signals. The company is expected to present top-line data during the summer of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.35 SEK | +6.06% | +25.00% | +34.62% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+34.62% | 11.52M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- ANNX Stock
- News Annexin Pharmaceuticals AB
- Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals